ArticleJournal of medical case reports2026
Intravenous trimethoprim-sulfamethoxazole desensitization as a therapeutic strategy for late-onset Pneumocystis jirovecii pneumonia in a kidney transplant recipient: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPneumocystis jirovecii pneumonia is a potentially fatal opportunistic infection in kidney transplant recipients under intensified immunosuppression. Although most cases occur within the first post-transplant year, late-onset infections may develop after rituximab therapy or discontinuation of prophylaxis. Trimethoprim-sulfamethoxazole is the preferred agent for prevention and treatment, but allergy or intolerance limits its use. Desensitization protocols may allow reintroduction of this drug in selected patients. CASE PRESENTATION: A 37-year-old white female kidney transplant recipient presented with progressive dyspnea and deteriorating renal function 9 years after receiving a living donor kidney transplant from her brother. She had Alport-syndrome-related nephrotic syndrome and chronic kidney disease and had been treated for chronic antibody-mediated rejection with pulse corticosteroids, intravenous immunoglobulin, and rituximab. Pneumocystis jirovecii pneumonia prophylaxis was omitted because of a prior trimethoprim-sulfamethoxazole allergy. On admission, serum creatinine was 4.97 mg/dL, C-reactive protein was 56 mg/L, and chest computed tomography revealed diffuse ground-glass opacities. Other infectious causes were excluded. A presumptive diagnosis of Pneumocystis jirovecii pneumonia was made, and intravenous trimethoprim-sulfamethoxazole was given using a graded desensitization protocol, starting with a 1:1000 dilution and gradually increasing every 30-60 minutes. No hypersensitivity reactions occurred. Clinical improvement was observed within 1 week, and follow-up imaging showed near-complete resolution of pulmonary infiltrates.
conclusionThis case shows that late-onset Pneumocystis jirovecii pneumonia may develop years after transplantation, particularly after rituximab therapy and without prophylaxis. Intravenous trimethoprim-sulfamethoxazole desensitization can be a safe and effective therapeutic option for transplant recipients with a trimethoprim-sulfamethoxazole allergy, enabling use of the optimal antimicrobial agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.